Literature DB >> 2147900

A 10-year matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis.

L Kappos1, R Heun, H G Mertens.   

Abstract

In a retrospective matched-pairs study the efficacy of azathioprine treatment was compared with no treatment over a period of at least 10 years. Of 277 patients with clinically definite multiple sclerosis seen during the years 1973 and 1974, 42 pairs were selected by similarity in disability score, sex, age and disease duration. Only 3 patients were lost to follow-up, and in 2 cases the initial diagnosis could not be confirmed. At the end of the 10-year period the number of wheelchair-bound, bedridden or deceased patients was double in the untreated as compared with the azathioprine-treated group but the number of non- or only minimally handicapped patients was similar in each group. The mean disability score was significantly lower in the treated group. Although caution is warranted as in every retrospective study because of insufficiently controlled confounding variables, these results support a positive but weak long-term effect of azathioprine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147900     DOI: 10.1007/bf02190090

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  17 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.

Authors:  G W Ellison; L W Myers
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

Review 3.  Autoimmunity in demyelinating diseases.

Authors:  B H Waksman
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  [Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982].

Authors:  G Aimard; C Confavreux; J J Ventre; M Guillot; M Devic
Journal:  Rev Neurol (Paris)       Date:  1983       Impact factor: 2.607

5.  Factors associated with a malignant or benign course of multiple sclerosis.

Authors:  V A Clark; R Detels; B R Visscher; N L Valdiviezo; R M Malmgren; J P Dudley
Journal:  JAMA       Date:  1982-08-20       Impact factor: 56.272

6.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

7.  [Immunosuppressive treatment of multiple sclerosis. 4. Results of treatment with azathioprine and antilymphocyte globulin (author's transl)].

Authors:  E Frick; H Angstwurm; R Blomer; G Strauss
Journal:  MMW Munch Med Wochenschr       Date:  1977-09-02

8.  [Immunsuppressive treatment of multiple sclerosis. 2. Critical review of general results (author's transl)].

Authors:  E Frick; H Angstwurm; G Strauss
Journal:  MMW Munch Med Wochenschr       Date:  1974-11-08

9.  Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.

Authors:  U Patzold; H Hecker; P Pocklington
Journal:  J Neurol Sci       Date:  1982-06       Impact factor: 3.181

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  2 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients.

Authors:  Roland Windt; Gerd Glaeske; Falk Hoffmann
Journal:  Int J Clin Pharm       Date:  2013-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.